Pfizer Inc. (PFE)

42.99
NYSE : Health Technology
Prev Close 43.76
Day Low/High 42.50 / 43.80
52 Wk Low/High 36.00 / 46.47
Avg Volume 21.55M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 242.95B
EPS 1.90
P/E Ratio 23.03
Div & Yield 1.44 (3.20%)
Sangamo Stock Soars on Positive Hemophilia Treatment Trial

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

- Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc.

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer pays $51 million up front for a 15% stake in French biopharmaceutical company Vivet.

Pfizer Secures Exclusive Option To Acquire Gene Therapy Company Vivet Therapeutics

Pfizer Secures Exclusive Option To Acquire Gene Therapy Company Vivet Therapeutics

Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc.

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc.

Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Using Technical Analysis: Cramer's 'Mad Money' Recap (Monday 3/18/19)

Using Technical Analysis: Cramer's 'Mad Money' Recap (Monday 3/18/19)

Jim Cramer explains the art and science of technical analysis.

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

AUGUSTUS Demonstrates Favorable Safety Results Of Eliquis® Versus Vitamin K Antagonists In Non-Valvular Atrial Fibrillation Patients With Acute Coronary Syndrome And/or Undergoing Percutaneous Coronary Intervention

The Bristol-Myers Squibb- Pfizer Alliance today announced results from the Phase 4 AUGUSTUS trial evaluating Eliquis ® (apixaban) versus vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) and recent acute coronary...

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

Broker Darlings Of The Dow: Pfizer Ranks As A Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #14 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #258 spot.

U.S. FDA Approves Pfizer's Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), A Biosimilar To Herceptin®1

U.S. FDA Approves Pfizer's Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), A Biosimilar To Herceptin®1

Pfizer Inc. (NYSE: PFE) today announced the United States (U.

Could Kroger Lose the Grocery Wars Over This Challenge?

Could Kroger Lose the Grocery Wars Over This Challenge?

Allergan is another stock that could stay stuck in its Doldrums. See which of its peers Jim Cramer likes better and why.

Dow Ends Lower as Investors Eye Details From Trade Talks, Oil Prices Tumble

Dow Ends Lower as Investors Eye Details From Trade Talks, Oil Prices Tumble

The Dow Jones Industrial Average ended the day lower as details over the trade talks between the U.S. and China are awaited and oil prices tumble.

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes

AnTolRx Announces Pfizer Exercises Option To License Immune Tolerance Therapy For Potential Treatment Of Type 1 Diabetes

CAMBRIDGE, Mass., March 5, 2019 /PRNewswire/ -- AnTolRx, Inc.

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Chief Development Officer, Oncology, at the Cowen and Company 39 th Annual Healthcare...

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Prices $5,000,000,000 Debt Offering

Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of five tranches of notes: $500,000,000 aggregate principal amount of 2.

Pfizer Receives Positive CHMP Opinion For LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Receives Positive CHMP Opinion For LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for LORVIQUA ® (lorlatinib, approved in the U.

Pfizer Becomes #1 Most Shorted Dow Stock, Replacing Walgreens Boots Alliance

Pfizer Becomes #1 Most Shorted Dow Stock, Replacing Walgreens Boots Alliance

The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Pfizer Announces Serotypes Included In 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Announces Serotypes Included In 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Inc. (NYSE: PFE) announced today the new serotypes included in its 20-Valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae...

Johnson & Johnson Subpoenaed for Talc Safety Information

Johnson & Johnson Subpoenaed for Talc Safety Information

Johnson & Johnson says it will comply with the subpoenas for information related to its iconic baby powder.

Ochsner Health System And Pfizer Partner To Develop Innovative Models For Clinical Trials

Ochsner Health System And Pfizer Partner To Develop Innovative Models For Clinical Trials

Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials.

Pfizer Receives European Approval For ZIRABEV™ (bevacizumab), A Biosimilar To Avastin®*

Pfizer Receives European Approval For ZIRABEV™ (bevacizumab), A Biosimilar To Avastin®*

Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung...

Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain

Pfizer And Lilly Announce Top-line Results From Phase 3 Study Of Tanezumab In Chronic Low Back Pain

NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc.

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

3 Pet Product Stocks Ready to Be Unleashed: Dogness, Elanco and Zoetis

Pets can bring significant profits to companies that cater to this niche market.

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.

TheStreet Quant Rating: B (Buy)